Collectively, these results suggest that epithelial–mesenchymal plasticity is associated with cGAS–STING activation in chromosomally unstable NSCLC with EGFR-activating mutations and may limit the clinical outcome of EGFR-TKI treatment (Figure 5E). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.